Results 81 to 90 of about 3,817,010 (199)
Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity
COVID-19, a novel coronavirus pneumonia (named by the World Health Organization, WHO), has spread widely since the end of 2019. Research on synthetic drugs and vaccines has become a focus of attention in China and other countries, as such approaches are ...
Jin Zhou, Jie Huang, Jie Huang
doaj +1 more source
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca +18 more
wiley +1 more source
De toda la población infectada por el SARS-CoV-2, la población pediátrica representa del 1 al 5%, siendo un reto caracterizarla clínicamente. Presentamos cinco casos de pacientes pediátricos con diagnóstico de COVID-19; el rango de edad fue de 1 a 14 ...
Héctor Nuñez-Paucar +7 more
doaj +1 more source
ABSTRACT The emergence of diverse SARS‐CoV‐2 Omicron subvariants has reduced the efficacy of existing vaccines, highlighting the need for multivalent vaccines with broader neutralizing capacity. We developed a trivalent adenoviral vector‐based vaccine (Ad5‐CoV19‐prototype/Delta/BF.7) encoding the spike proteins of the ancestral strain, Delta variant ...
Jianhua Li +7 more
wiley +1 more source
Potentially highly potent drugs for 2019-nCoV [PDF]
Abstract The World Health Organization (WHO) has declared the 2019 novel coronavirus (2019-nCoV) infection outbreak a global health emergency. Currently, there is no effective anti-2019-nCoV medication. The sequence identity of the 3CL proteases of 2019-nCoV and SARS is 96%, which provides a sound foundation for structural-based drug ...
Nguyen, Duc Duy +4 more
openaire +2 more sources
Promising Inhibitor for 2019-nCoV in Drug Development
The 2019 novel coronavirus (2019-nCoV), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have taken by the Chinese government to control the pandemic of the ...
Zilong Dang, Xiaohui Xu
core +1 more source
A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China. Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health ...
Jasper Fuk-Woo Chan +6 more
doaj +1 more source
Inspired by viral entry mechanisms, the FUSION assay enables autonomous detection of respiratory viruses via membrane fusion–triggered CRISPR‐Cas13a activation. VEACON selectively fuses with fusion‐competent viruses, triggering fluorescence within confined vesicles.
Jae Chul Park +15 more
wiley +1 more source
Structure analysis of the receptor binding of 2019-nCoV
2019-nCoV is a newly identified coronavirus with high similarity to SARS-CoV. We performed a structural analysis of the receptor binding domain (RBD) of spike glycoprotein responsible for entry of coronaviruses into host cells. The RBDs from the two viruses share 72% identity in amino acid sequences, and molecular simulation reveals highly similar ...
Chen, Yun +3 more
openaire +2 more sources
Sensitive and Spatially‐Resolved Electrochemiluminescence via Micropatterning
The use of a simple silica nanoparticle surface coating and patterning process can transform ordinary gold electrodes into multiplexed ECL sensing electrodes. Through spatially confined droplet formation and local ECL emission, it is possible to perform multiple analyses simultaneously from individual locations as well as intensify the ECL signal by as
Yuliang Shao +12 more
wiley +1 more source

